UCLA KRAS Vaccine Shows Promising Results in Cancer Trial
A phase 1 trial of the ELI-002 2P vaccine, led by UCLA Health researchers, showed strong immune responses in 25 patients with pancreatic or colorectal cancer. The study found that 84% of participants generated KRAS-specific T cells, with promising results for relapse-free and overall survival.
A groundbreaking study published on September 1, 2026, in Nature Medicine highlights the promising results of a new off-the-shelf cancer vaccine known as ELI-002 2P. This vaccine was developed to target the KRAS mutations prevalent in pancreatic and colorectal cancers, and it showed strong immune responses in a cohort of 25 patients. Conducted by researchers at the UCLA Health Jonsson Comprehensive Cancer Center, the trial demonstrated that 84% of the participants developed KRAS-specific T cells. These findings suggest that ELI-002 2P could represent a significant advancement in the fight against cancers that are notoriously difficult to treat, such as pancreatic cancer, where effective therapies are limited and recurrence is common. The study indicates the potential of the vaccine to help prevent or delay cancer recurrence in high-risk patients with KRAS mutations, marking a hopeful milestone in cancer treatment.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Priya reports on breakthroughs that change lives, big and small.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
